ATLCAR.CD30.CCR4

N/A

Report date: 2026/02/03 20:00:14

Base Information

Drug NameATLCAR.CD30.CCR4
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 8C-C chemokine receptor type 4 antagonists
TargetsTumor necrosis factor receptor superfamily member 8C-C chemokine receptor type 4
Therapy Area/IndicationsImmunoproliferative DisordersImmune System DiseasesLymphoproliferative Disorders +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsImmunoproliferative DisordersLymphoproliferative DisordersLymphatic Diseases +[9] 
Inactive IndicationsImmune System DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A